Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Small interfering RNA Stories

2011-12-20 08:07:00

SEATTLE, Dec. 20, 2011 /PRNewswire/ -- Nature Reviews Genetics (NRG) and Arkitek today jointly announce the launch of a new version of the popular RNA interference animation originally launched on NRG's site in 2004. Arkitek and Nature Reviews Genetics decided to update the RNAi animation to showcase the new information learned about the functions of small RNAs. To view the multimedia assets associated with this release, please visit:...

2011-12-20 01:00:00

LONDON, December 20, 2011 /PRNewswire/ -- Silence Therapeutics plc [http://www.silencetherapeutics.com ] (AIM: SLN) ("Silence" or the "Company") a leading global RNA [http://silence-therapeutics.com/content/scienceofrnai/overview.htm ]interference (RNAi) therapeutics company, today announces that application has been sought for 530,000 new ordinary shares of 1 pence each ("Ordinary Shares") to be admitted to trading on AIM. The new Ordinary Shares are being issued in accordance...

2011-12-12 15:50:00

AUSTIN, Texas, Dec. 12, 2011 /PRNewswire/ -- Altogen Labs (www.altogenlabs.com) has announced the release of a new contract research services (CRO) product: small interfering RNA (siRNA) liposome encapsulation, a technique used in biology laboratories to enable in vivo delivery of siRNA (http://altogenlabs.com/services/rnai_services/sirna_liposome_encapsulation_service). Liposome encapsulation platform uses latest microfluidizer (Microfluidics) technology and is unique in its ability to...

2011-12-12 01:00:00

LONDON, December 12, 2011 /PRNewswire/ -- Silence Therapeutics plc [http://www.silencetherapeutics.com ] (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi [http://www.silencetherapeutics.com/content/scienceofrnai/overview.htm ]) therapeutics company, announces that the United States Patent and Trademark Office (USPTO) has completed its reexamination of four key RNAi patents that form part of the foundational "Zamore Design Rule" patent families....

2011-12-07 08:11:00

LONDON, December 7, 2011 /PRNewswire/ -- Silence Therapeutics plc [http://www.silencetherapeutics.com ] (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi [http://www.silencetherapeutics.com/content/scienceofrnai/overview.htm ]) therapeutics company, announces a positive outcome from the oral hearing on 6 December 2011 at the European Patent Office (EPO) over opposition to Silence's granted European Patent EP 1 536 827 "Further use of protein kinase N...

2011-11-08 07:30:00

DALLAS and NEW YORK, Nov. 8, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major player in RNAi industry to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics. Access will provide the pharmaceutical company with CobOral and...

2011-11-08 01:00:00

LONDON, November 8, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi [http://www.silence-therapeutics.com/content/scienceofrnai/overview.htm ]) therapeutics company, today provides an update on recent business and clinical developments. Expansion of business development team Silence today announces the appointment of Dr Georg Buchner as VP Business Development. Georg will work with Tony...

2011-10-12 10:03:51

Short interfering RNAs induce retinal degeneration via TLR3 and IRF3 According to new research by University of Kentucky investigators, an emerging pharmaceutical platform used in treating a variety of diseases may produce unintended and undesirable effects on eye function. The paper, "Short-interfering RNAs Induce Retinal Degeneration via TLR3 and IRF3", appears in the current online edition of the journal Molecular Therapy, a publication of the Nature Publishing Group and the American...

2011-10-11 07:01:00

PHILADELPHIA and REHOVOT, Israel, Oct. 11, 2011 /PRNewswire/ -- Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that it has executed a license agreement with Avatao Biotech, a leading biotechnology company developing and distributing cutting-edge diagnostic products in China, for the exclusive rights to market miRview® mets and miRview® mets(2) , Rosetta's microRNA-based...

2011-10-10 09:12:58

Interfering with cell recruitment reduces damaging inflammation in animals´ models of several disorders Massachusetts General Hospital (MGH) researchers — along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals — have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication in Nature Biotechnology, the investigators...